Which country? [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-09-10 01:17 (1541 d 07:15 ago) – Posting: # 20566
Views: 8,313

Hi Elena,

❝ We are planning to conduct several BE studies with adaptive design using the drugs with uncertain intraCV. We have decided to use method C described by Potvin …


Whether Potvin’s Method C will be accepted depends on the jurisdiction you are bound to.a,b
More information please.


  1. Accepted by the FDA (Donald Schuirmann is a co-author of this paper and later ones) and Health Canada. Confirmed at the 2nd/3rd GBHI conferences (Rockville 2016, Amsterdam 2018) that any simulation-based method is acceptable.
  2. For the EMA possible if BE already in stage 1, difficult if you proceeded to stage 2. Even Method B is tricky. The EMA dislikes (oh dear!) methods based on simulations and prefers ones which showed strict control of the type I error, i.e.,
    1. König F, Wolfsegger M, Jaki T, Schütz H, Wassmer G. Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation. Vienna: 2014; 35th Annual Conference of the International Society for Clinical Biostatistics. Poster P1.2.88. doi:10.13140/RG.2.1.5190.0967.
    2. Maurer W, Jones B, Chen Y. Controlling the type 1 error rate in two-stage sequential designs when testing for average bioequivalence. Stat Med. 2018;37(10):1–21. doi:10.1002/sim.7614.
    BTW, implemented in the [image]-package Power2Stage: functions power.2stage.in(), interim.tsd.in(), final.tsd.in() since October 2017.
    The EMA’s Pharmacokinetics Working Party and the Biostatistics Working Party had two-stage design on their workplan for years (!) with any outcome. At last year’s BioBridges Paola Cop­pola (MHRA) showed this slide:

    [image]

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,811 posts in 4,783 threads, 1,642 registered users;
15 visitors (0 registered, 15 guests [including 6 identified bots]).
Forum time: 07:32 CET (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5